103results about How to "Increase urine output" patented technology

A device for draining bodily fluids is described herein which generally may comprise an elongate body defining one or more lumens configured to receive a bodily fluid from a cavity, e.g., bladder, of a patient body. The one or more lumens are in fluid communication with a reservoir which may receive the bodily fluid. A pumping mechanism may be used to urge the bodily fluid through the one or more lumens, where the pumping mechanism is configured to maintain an open space within the one or more lumens such that outflow of the bodily fluid through the one or more lumens remains unobstructed such that a negative pressure buildup in the cavity is inhibited. The device may also include a vent or valve mechanism in communication with the elongate body to allow air to enter or exit the one or more lumens.

Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.

A Chinese medicine for preventing and treating cerebral apoplexy is prepared from 63 Chinese-medicinal materials including astragalus root, ginseng, Chinese angelica root, scorpion, etc through pulverizing and proportionally mixing.

In one aspect, the present invention is directed to an apparatus and method for treating congestive heart failure that restores kidney renal functions by artificial perfusion of at least one kidney. In one aspect, a catheter inserted into the aorta of the patient has an outlet port that supplies the patient's blood obtained from a patient's aorta into an adjoining renal artery of the patient to perfuse the kidney. The catheter comprises a rotor housed inside a portion of the catheter to supply the blood to the kidney at a desired pressure. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

A device for measuring of urine production of a patient carrying a urine catheter, the device comprising a replaceable self-emptying chamber (120), provided with a siphon for self emptying when the burette becomes filled up to a predetermined volume, the self-emptying chamber further comprises an inlet and an outlet for the urine whose volume is to be measured, further, the device comprises a base unit (105) provided with attachment organs for removably attaching the self-emptying chamber (120) to the base unit, which station having measurement organs for sensing the level of urine in the self-emptying chamber and for keeping track of number of self-emptyings.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.

The present invention discloses clerodendranthus spiatus extract for treating urinary calculus and its preparation process, and belongs to the field of Chinese herbal medicine extract and application technology. The clerodendranthus spiatus extract preparing process includes the following steps: soaking clerodendranthus spiatus in 4-10 times methanol to extract and concentrating to obtain extractum; dissolving the extractum in solvent in the same volume; extracting the solution first with petroleum ether and then with ethyl acetate and concentrating to obtain coarse extract; and chromatographic separation, eluting, collecting and concentrating to operate clerodendranthus spiatus extract A. The clerodendranthus spiatus extract A is liposoluble flavone glycoside compound and has obvious urinary calculus treating effects.

Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.

The invention discloses an okra juice drink and a preparation method therefor. The drink comprises the following ingredients, by weight, 45 parts of okra original juice, 4 parts of white granulated sugar, 0.5 part of xylitol, 0.01 part of sucralose, 0.1 part of citric acid, 0.01 part of tartaric acid, 0.03 part of sodium citrate, 0.01 part of glycine, 0.03 part of taurine, 0.03 part of vitamin C, 50.28 parts of purified water for drinking and 0.08-0.1 part of essence. The drink has good taste, and is beneficial for absorption of nutrition and health care components in human body. The bioavailability of active ingredients is raised, and the drink is suitable for popularization and application.

A device for measuring of urine production of a patient carrying a urine catheter, the device comprising a replaceable self-emptying chamber (120), provided with a siphon for self emptying when the burette becomes filled up to a predetermined volume, the self-emptying chamber further comprises an inlet and an outlet for the urine whose volume is to be measured, further, the device comprises a base unit (105) provided with attachment organs for removably attaching the self-emptying chamber (120) to the base unit, which station having measurement organs for sensing the level of urine in the self-emptying chamber and for keeping track of number of self-emptyings.

The invention refers to the herbal composition which consists of: the plant of centaury (Centauri herba) 12.3% by wt., the root of dandelion (Teraxaci radix) 9.7% by wt., the fruit of juniper (Juniperi communis fructus) 6.2% by wt., the plant of nettle (Urticae herba) 7.4% by wt., the root of nettle (Urticae radix) 7.0% by wt., the root of chicory (Cichorii radix) 17.7% by wt., the leaf of black mulberry (Morus nigra folium) 7.4% by wt., the flower of yarrow (Achilleae millefolii flos) 3.5% by wt., the leaf of bilberry (Vaccinii myrtilli folium) 6.6% by wt., the pod of beans (Phaseoli fructus sine semeni) 14.4% by wt., and the root of valerian (Valerianae officinalis radix) 7.8% by wt., and to the medicament against diabetes mellitus type II obtained from it. The medicament is anticipated to be administered perorally in form of tea, a tincture and a pill.

Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does not exceed a serum theophylline level of 15-20 micrograms / ml, most preferably the aminophylline is administered to achieve a serum theophylline concentration of 3-10 micrograms / ml, with an infusion rate of 0.1-0.6 mg / kg IBW / hour (IBW=ideal body weight). The adenosine receptor antagonist can also be used to help sustain a kidney for transplant purposes. Preferably, aminophylline is loaded while the kidney is still part of the donor. A dose of aminophylline of 5 mg / kg lean body weight is infused into the donor over a 30-60 min period, with cardiac monitoring. The infusion dose is decreased in the event of supraventricular or ventricular tachycardias. The kidney is removed and placed in the standard “cold” bath, but containing aminophylline at a dose of 5-10 micrograms / ml (5-10 mg / l). The kidney is then transported to the recipient. The recipient is similarly preloaded with 5 mg / kg lean body mass aminophylline intravenously over 30-60 min with cardiac monitoring, with a constant infusion of 0.1-0.3 mg / kg lean body mass / hr continuing during the next 24 hours after the kidney is transplanted into the recipient.

A method to protect kidneys of a patient undergoing cardiac surgery patient including: administrating a diuretic to the patient to increase urine output of the patient during cardiac surgery, wherein the diuretic is administered during the cardiac surgery; anesthetizing the patient with a general anesthetic during the cardiac surgery; infusing an intravenous liquid into the patient during the cardiac surgery; monitoring a rate or amount of urine output of the patient during the cardiac surgery, and automatically adjusting a rate or amount of the intravenous liquid infused into the patient to achieve or exceed a target urine output during the cardiac surgery.

A device for draining bodily fluids is described herein which generally may comprise an elongate body defining one or more lumens configured to receive a bodily fluid from a cavity, e.g., bladder, of a patient body. The one or more lumens are in fluid communication with a reservoir which may receive the bodily fluid. A pumping mechanism may be used to urge the bodily fluid through the one or more lumens, where the pumping mechanism is configured to maintain an open space within the one or more lumens such that outflow of the bodily fluid through the one or more lumens remains unobstructed such that a negative pressure buildup in the cavity is inhibited. The device may also include a vent or valve mechanism in communication with the elongate body to allow air to enter or exit the one or more lumens.

The invention relates to a tea for enlivening spleens and a production method of the tea. The tea is produced by the following components at a certain weight ratio: radix astragali, bighead atractylodes rhizome, angelica sinensis, rhizoma alismatis, radix bupleuri, radix paeoniae alba, tangerine peel, codonopsis pilosula, common yam rhizome, stir-fried fructus aurantii, rhizoma cyperi, dark plum, trichosanthes kirilowii maxim, rhizoma atractylodis, rhizoma acori graminei, mangnolia officinalis, medicated leaven, hawthorn, poria cocos, and black tea. The tea is reasonable in formulation, simple to produce, easy to preserve, appropriate in four seasons, convenient to drink, and appropriate in taste, has the function of integrating all medicine components for enlivening the spleens and allowing the medicine components to exert a synergetic effect, thereby realizing efficacies of replenishing qi, invigorating the spleens, removing dampness, promoting diuresis, regulating middle energizers, promoting the circulation of qi, dispelling phlegm, inducing reuscitation, removing blood stasis, and eliminating stagnation; people with pathogenic dampness and the encumbered spleens can select according to different clinical manifestations and symptoms; and the incidence of diseases with the major manifestations of tiredness and sleepiness induced by various causes can be reduced.

Disclosed is a Chinese medicinal suppository for treating chronic prostatitis and its preparing process, wherein the raw materials include corktree bark, dandelion, Herba Corydalis bungeanae, creat, root of red rooted saliva, radix paeoniae rubrathe, dragon's blood resin, boneol, plantain herb, and mixed fatty acid glycerol ester.

Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-ARnYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4′)-biphenylalanine or D-(4,4′)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.

The invention discloses a series of urea transporter inhibitors of which the structural formula is disclosed in the specification. An erythrocyte model is used for screening to obtain compounds for inhibiting urea transporters. The experimental result indicates that the compounds (such as Youti) can inhibit the permeation of urea transporter UT-B mediated erythrocyte membranes for urea, and the action forms a dosage dependency relationship; Youti within effective dose range has no cytotoxic action on the MDCK (Madin-Darby Canine Kidney) cells, which indicates that the action of Youti for inhibiting cell permeable urea is irrelevant to cytotoxicity; the inhibiting action of Youti on the urea transporter UT-B gradually increases; the inhibiting action of Youti on the urea transporter UT-B is reversible; and the in-vivo test result proves that Youti can obviously increase the uresis amount of a rat, lower the concentration of urea in the urine of the rat, and lower the osmotic pressure, which indicates that Youti has selective diuresis action on urea in vivo.

The invention discloses a health protection and uric acid decreasing tea bag and a preparation method thereof. The tea bag comprises the following components by mass ratio: 50 to 70 parts of prepared radix gentianae macrophyllae, 190 to 210 parts of ash bark, 30 to 50 parts of prepared clematis root, 90 to 110 parts of glandularstalk St.Paulswort herb, 90 to 110 parts of bidens, 90 to 110 parts of stringy stonecrop herb, 110 to 130 parts of honeysuckle, and 190 to 210 parts of green tea. Through raw material culling, sterilizing, and drying and mixing, the components are pulverized into fine powders with 60 meshes, and then are subpackaged by tea bag filter paper into tea bags. The tea bag uses tea to act as medicine, accelerates the excretion of uric acid, reduces uric acid content, achieves the effect of curing gout disease, and has the advantages of fast effect, no toxic or side effect, and economical and practical benefit.

The invention discloses a traditional Chinese medicine preparation used for curing diseases of prostate and a preparation method thereof. The preparation is made from the active drug ingredients processed by mulberry syncarp, Gorgon fruit, Sevenlobed Yam Rhizome, cherokee rose and cape jasmine and a pharmaceutically acceptable carrier according to a certain proportion by processing. The carrier is starch. Compared with the prior art, the traditional Chinese medicine preparation provided by the invention has obvious curative effects when being used for treating prostatitis and hyperplasia of prostate gland.

The present invention discloses a Chinese medicine for curing nongonococcal urethritis and its preparation method. Said medicine is made up by using 6 Chinese medicinal materials of gardenia fruit, astragalus root, hedyotis, ophiopogon tuber, mallow seed and picrasma quassioides as raw material through a certain preparation process. Said medicine has the functions of clearing heat, disinhibiting dampness, boosting qi, nourishing yin and inducing diuresis for treating stranguria, and possesses the action of resisting inflammation, resisting bacteria, raising immunity and stopping pain.

The invention relates to a traditional Chinese medicine health care tea, and in particular to a fat-reducing slimming tea and a preparation process thereof. The fat-reducing slimming tea is prepared from the following raw materials by weight: 12-15 parts of lotus leaf, 10-20 parts of cassia seed, 9-20 parts of hawthorn and 9-20 parts of rhizoma alismatis. The tea employs a pure traditional Chinese herbal prescription, which has no toxic or side effect on the human body, can reduce fat and help lose weight, and is applicable to the obese people with elevated blood lipids.

The invention discloses a urinary tract protection feed additive for dogs and cats and a preparation method thereof, the urinary tract protection feed additive for dogs and cats comprises 10-40 parts by weight of a clerodendranthus spicatus extract, 20-40 parts by weight of plantain seeds, 5-10 parts by weight of turmeric powder and 40-60 parts by weight of a dispersant, and the dispersant is wheat bran. The preparation method of the urinary tract protection feed additive for dogs and cats comprises the following steps: a) preparing a clerodendranthus spicatus extract; and b) mixing. When the addition amount of the additive is about 1%, the water intake of dogs and cats can be remarkably increased, the urination amount and urination times are increased, and metabolic end products accumulated in serum are discharged accordingly, so that the content of urea nitrogen in the serum is remarkably reduced, the content of serum protein is not remarkably changed, and the nitrogen balance of dogs and cats is not influenced.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.

The present invention discloses a clerodendranthus spicatus extract capable of resisting urinary lithiasis and its preparation method, belonging to the field of Chinese medicinal material extract and application technology. Said method includes the following several steps: (1), mixing clerodendranthus spicatus and methyl alcohol according to the ratio of weight: volume=1:4-10, soaking, extracting and concentrating to obtain extract mixture; (2), mixing said extract mixture and dissolving liquor according to the ratio of weight:volume=1:1, dissolving; (3), firstly, using petroleum ether to extract the dissolved liquor, then using ethyl acetate to make secondary extraction, concentrating so as to obtain extract; and (4), making above-mentioned obtained extract undergo the processes of chromatography, elution, collection and concentration so as to obtain the invented cleodendranthus spicatus extract component A. Said cleodendranthus spicatus extract component A belongs to a fat-soluble flavone aglucone compound, said compound can be used for preparing the medicine with the functions of improving litholysis, promoting lithecbole, diuresis and relieving inflammation, etc.

The invention discloses an application of a urea transporter (UT) inhibitor Youti, of which the structural formula is represented as the formula I. In the invention, by means of erythrocyte model screening, the compound inhibiting the UT is obtained. An experimental result proves that the compounds, such as the Youti, can inhibit the permeability, induced by the UT-B, of urea through erythrocytes membrane, wherein the effect of the Youti has a dosage dependent relationship. In an effective dosage range, the Youti is free of cyto-toxicity on MDCK cells, which proves that the effect of inhibition the permeability of the urea through cells by the Youti is independent of the cyto-toxicity. The Youti is gradually enhanced in the inhibition effect on the UT-B and the inhibition effect of the Youti on the UT-B is reversible. An in-vivo test result proves that the Youti can significantly increase the urine output of mice, can reduce the concentration of urea in the urine of mice and can reduce the osmotic pressure, so that it is proves that the Youti has a urea-selective diuretic effect in-vivo.

The present invention discloses a clerodendranthus spicatus extract for resisting urinary lithiasis and its preparation method, belonging to the field of Chinese medicinal material extract and application technology. Said method includes the following steps: (1), soaking the cleodendranthus spicatus and methyl alcohol according to the ratio of weight:volume=1:4-10, extracting and concentrating so as to obtain extract mixture; (2), mixing said extract mixture and dissolving liquor according to the ratio of weight:volume=1:1 and dissolving; (3), firstly, using petroleum ether to extract said dissolved liquor, then using ethyl acetate to make secondary extraction, concentrating to obtain extract; and (4), making the above-mentioned obtained extract undergo the processes of chromatography, elution, collection and concentration so as to obtain the invented cleodendranthus spicatus extract component A. Said component A belongs to a fat-soluble flavone aglucone compound which can be used for preparing the medicine with the excellent effect for improving litholysis, promoting lithecbole, diuresis and relieving inflammation, etc.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.